Kelly Seaton, Ph.D.
Affiliations: | 2009 | Pennsylvania State University, State College, PA, United States |
Area:
Pharmacology, Virology BiologyGoogle:
"Kelly Seaton"Mean distance: 42746.4
Parents
Sign in to add mentor| Jong K. Yun | grad student | 2009 | Penn State | |
| (The human N-myristoyltransferases as potential pharmacotherapeutic targets in HIV-1 replication.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Frank I, Li SS, Grunenberg N, et al. (2024) Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial. The Lancet. Hiv. 11: e285-e299 |
| Moodie Z, Andersen-Nissen E, Grunenberg N, et al. (2024) Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. Plos Medicine. 21: e1004360 |
| Walsh SR, Gay CL, Karuna ST, et al. (2024) A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087). Medrxiv : the Preprint Server For Health Sciences |
| Reeves DB, Mayer BT, deCamp AC, et al. (2023) High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nature Communications. 14: 8299 |
| Sobieszczyk ME, Mannheimer S, Paez CA, et al. (2023) Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administered intravenously to HIV-uninfected adults: a phase 1 randomised trial. The Lancet. Hiv. 10: e653-e662 |
| Chirenje ZM, Laher F, Dintwe O, et al. (2023) Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120. The Journal of Infectious Diseases |
| Tieu HV, Karuna S, Huang Y, et al. (2023) Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US. Vaccine |
| Seaton KE, Huang Y, Karuna S, et al. (2023) Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. Ebiomedicine. 93: 104590 |
| Mayer-Blackwell K, Johnson AM, Potchen N, et al. (2022) Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines. Frontiers in Immunology. 13: 983313 |
| Huang Y, Zhang Y, Seaton KE, et al. (2022) Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens. Ebiomedicine. 84: 104271 |